Chembio Diagnostics and its subsidiaries develop, manufacture, and commercialize point-of-care diagnostic tests that are used to detect and diagnose diseases. The company's product commercialization and product development activities are focused on infectious disease testing and technology collaborations. In infectious disease, the company is commercializing tests for human immunodeficiency virus and Syphilis, Zika virus, and developing tests for malaria, dengue virus, chikungunya virus, ebola, lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi, individually or as part of fever panel tests.

SecureWorks is a holding company. Through its subsidiaries, the company provides information security solutions focused on protecting its customers from cyber attacks. The company's integrated suite of solutions include: managed security, through which it provides its customers global visibility and insight into malicious activity enabling them to detect and remediate threats; and security and risk consulting, through which it advises its customers on a variety of security and risk-related matters. The company's proprietary Counter Threat Platform collects, aggregates, correlates and analyzes daily events from its customer base and uses algorithms to detect malicious activity and deliver security countermeasures.